Influence of the Arene Ligand and the Leaving Group on the Anticancer Activity of (Thio)maltol Ruthenium(II)-(η6-Arene) Complexes

被引:30
作者
Hanif, Muhammad [1 ]
Schaaf, Patricia [1 ]
Kandioller, Wolfgang [1 ]
Hejl, Michaela [1 ]
Jakupec, Michael A. [1 ]
Roller, Alexander [1 ]
Keppler, Bernhard K. [1 ]
Hartinger, Christian G. [1 ]
机构
[1] Univ Vienna, Inst Inorgan Chem, A-1090 Vienna, Austria
基金
奥地利科学基金会;
关键词
RUTHENIUM(II)-ARENE PTA COMPLEXES; MRI CONTRAST AGENTS; IN-VITRO; RUTHENIUM COMPLEXES; PRECLINICAL DEVELOPMENT; CHELATING-AGENTS; IRON OVERLOAD; PHASE-I; MALTOL; INHIBITORS;
D O I
10.1071/CH10232
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Maltol and its metal complexes have shown promising applications in medicinal chemistry. We report here the synthesis and characterization of Ru(eta(6)-arene)(halido) coordination compounds bearing maltol or thiomaltol ligands and studies on their behaviour in aqueous solution, their reactions with the DNA model guanosine 5'-monophosphate (5'-GMP) and their in vitro anticancer activity in human tumour cell lines. The compounds hydrolyze rapidly and quantitatively to the respective aqua species by exchange of the halido ligand. With pK(a) values of >8, such species would also be present in biological media and they proved reactive to 5'-GMP. The thiomaltol compounds show promising in vitro activity with IC50 values (50% inhibitory concentration) in the low micromolar range, whereas activity of the maltol complexes is marginal. Variation of the arene ligand (benzene, toluene, p-cymene or biphenyl) resulted only in minor changes in activity.
引用
收藏
页码:1521 / 1528
页数:8
相关论文
共 64 条
[1]   Thioamide Hydroxypyrothiones Supersede Amide Hydroxypyrothiones in Potency against Anthrax Lethal Factor [J].
Agrawal, Arpita ;
de Oliveira, Cesar Augusto F. ;
Cheng, Yuhui ;
Jacobsen, Jennifer A. ;
McCammon, J. Andrew ;
Cohen, Seth M. .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (04) :1063-1074
[2]   In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer [J].
Aird, RE ;
Cummings, J ;
Ritchie, AA ;
Muir, M ;
Morris, RE ;
Chen, H ;
Sadler, PJ ;
Jodrell, DI .
BRITISH JOURNAL OF CANCER, 2002, 86 (10) :1652-1657
[3]   Classical and non-classical ruthenium-based anticancer drugs: Towards targeted chemotherapy [J].
Ang, Wee Han ;
Dyson, Paul J. .
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, 2006, (20) :4003-4018
[4]   Rational Design of an Organometallic Glutathione Transferase Inhibitor [J].
Ang, Wee Han ;
Parker, Lorien J. ;
De Luca, Anastasia ;
Juillerat-Jeanneret, Lucienne ;
Morton, Craig J. ;
Lo Bello, Mario ;
Parker, Michael W. ;
Dyson, Paul J. .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2009, 48 (21) :3854-3857
[5]  
[Anonymous], 1992, International Tables for X-Ray Crystallography, VC.
[6]   Synthesis and antiviral evaluation of cyclic and acyclic 2-methyl-3-hydroxy-4-pyridinone nucleoside derivatives [J].
Barral, K ;
Balzarini, J ;
Neyts, J ;
De Clercq, E ;
Hider, RC ;
Camplo, M .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (01) :43-50
[7]   ARENE RUTHENIUM(II) COMPLEXES FORMED BY DEHYDROGENATION OF CYCLOHEXADIENES WITH RUTHENIUM(III) TRICHLORIDE [J].
BENNETT, MA ;
SMITH, AK .
JOURNAL OF THE CHEMICAL SOCIETY-DALTON TRANSACTIONS, 1974, (02) :233-241
[8]   (ETA-6-HEXAMETHYLBENZENE)RUTHENIUM COMPLEXES [J].
BENNETT, MA ;
HUANG, TN ;
MATHESON, TW ;
SMITH, AK .
INORGANIC SYNTHESES, 1982, 21 :74-78
[9]   Alkylaryl-amino derivatives of 3-hydroxy-4-pyridinones as aluminium chelating agents with potential clinical application [J].
Chaves, S ;
Gil, M ;
Marques, S ;
Gano, L ;
Santos, MA .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2003, 97 (01) :161-172
[10]   Combined chelation based on glycosyl-mono- and bis-hydroxypyridinones for aluminium mobilization: Solution and biodistribution studies [J].
Chaves, Silvia ;
Dron, Paul I. ;
Danalache, Florina A. ;
Sacoto, Diana ;
Gano, Lurdes ;
Santos, M. Amelia .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2009, 103 (11) :1521-1529